Latest filings (excl ownership)
F-3ASR
Automatic shelf registration (foreign)
12 Apr 24
20-F
2023 FY
Annual report (foreign)
10 Apr 24
6-K
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
10 Apr 24
F-3ASR
Automatic shelf registration (foreign)
6 Mar 24
6-K
Current report (foreign)
6 Mar 24
6-K
Pharvaris Announces Extraordinary Meeting of Shareholders
16 Feb 24
6-K
Registration Rights Agreement
7 Feb 24
6-K
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
22 Jan 24
6-K
Current report (foreign)
8 Jan 24
6-K
Current report (foreign)
8 Dec 23
424B5
Prospectus supplement for primary offering
7 Dec 23
FWP
Free writing prospectus
6 Dec 23
6-K
Current report (foreign)
6 Dec 23
6-K
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
424B5
Prospectus supplement for primary offering
24 Aug 23
EFFECT
Notice of effectiveness
17 Aug 23
CORRESP
Correspondence with SEC
15 Aug 23
UPLOAD
Letter from SEC
14 Aug 23
F-3
Shelf registration (foreign)
7 Aug 23
6-K
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
7 Aug 23
6-K
Current report (foreign)
3 Jul 23
6-K
Current report (foreign)
27 Jun 23
6-K
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
26 Jun 23
6-K
Current report (foreign)
23 Jun 23
6-K
Current report (foreign)
20 Jun 23
6-K
Pharvaris Announces Annual Meeting of Shareholders
1 Jun 23
6-K
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
8 May 23
6-K
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
5 Apr 23
20-F
2022 FY
Annual report (foreign)
5 Apr 23
6-K
Current report (foreign)
10 Mar 23
6-K
Current report (foreign)
8 Mar 23
6-K
Current report (foreign)
14 Feb 23
6-K
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
9 Jan 23
6-K
Current report (foreign)
8 Dec 22
6-K
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
8 Dec 22
6-K
Current report (foreign)
1 Nov 22
6-K
Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
12 Sep 22
6-K
6-K - Press Release 22.08.2022
22 Aug 22
6-K
Current report (foreign)
13 Jul 22
6-K/A
Current report (foreign) (amended)
1 Jul 22
Latest ownership filings
144
Notice of proposed sale of securities
23 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
15 Mar 24
144/A
Notice of proposed sale of securities (amended)
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
Foresite Capital Fund IV, L.P.
13 Feb 24
SC 13G/A
GENERAL ATLANTIC, L.P.
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
LSP V Cooperatieve U.A.
8 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
SC 13D/A
venBio Global Strategic Fund III, L.P.
25 Jan 24
SC 13G/A
Bain Capital Life Sciences Fund, L.P.
22 Jan 24
144
Notice of proposed sale of securities
2 Jan 24
144
Notice of proposed sale of securities
6 Dec 23
SC 13G
Venrock Healthcare Capital Partners III, L.P.
30 Nov 23
144
Notice of proposed sale of securities
17 Nov 23
144/A
Notice of proposed sale of securities (amended)
20 Sep 23
144
Notice of proposed sale of securities
19 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
144
Notice of proposed sale of securities
9 Aug 23
144
Notice of proposed sale of securities
9 Aug 23
144
Notice of proposed sale of securities
9 Aug 23
SC 13G/A
Bain Capital Life Sciences Fund, L.P.
23 Jun 23
SC 13G/A
GENERAL ATLANTIC, L.P.
23 Jun 23
SC 13D/A
venBio Global Strategic Fund III, L.P.
21 Jun 23
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 23
SC 13G/A
Foresite Capital Fund IV, L.P.
13 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13D/A
venBio Global Strategic Fund III, L.P.
26 Sep 22
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 22
SC 13G/A
Foresite Capital Fund IV, L.P.
11 Feb 22
SC 13G
FMR LLC
9 Feb 22
SC 13G
LSP V Cooperatieve U.A.
3 Feb 22
SC 13D
venBio Global Strategic Fund III, L.P.
19 Feb 21